Pompe Disease - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Pompe Disease Emerging Therapy and TPP Insights

Thelansis's "Pompe Disease Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Pompe Disease Overview

Pompe disease is a rare, progressive autosomal recessive lysosomal storage disorder caused by deficiency of acid alpha-glucosidase (GAA) - encoded by the GAA gene - resulting in pathological intralysosomal glycogen accumulation predominantly within skeletal, cardiac, and smooth muscle, causing irreversible cellular damage and organ dysfunction. Disease severity correlates inversely with residual GAA enzyme activity, producing a clinical spectrum ranging from classic infantile-onset Pompe disease - presenting within months of birth with hypertrophic cardiomyopathy, profound hypotonia, respiratory failure, and rapidly fatal course without treatment - to late-onset disease manifesting with progressive proximal myopathy, respiratory insufficiency, and preserved cardiac function across childhood or adulthood. Diagnosis integrates dried blood spot GAA enzyme activity assay as the primary screening tool, confirmed by GAA gene sequencing and muscle biopsy demonstrating lysosomal glycogen accumulation. Enzyme replacement therapy - alglucosidase alfa - established the therapeutic foundation, while cipaglucosidase alfa combined with the pharmacological chaperone miglustat represents a significant advancement, demonstrating superior glycogen clearance and clinically meaningful functional improvements over standard ERT. Respiratory surveillance with pulmonary function testing, nocturnal oximetry, and ventilatory support - including non-invasive ventilation - are critical management pillars. Physiotherapy and multidisciplinary rehabilitation optimise functional capacity. Prognosis has improved substantially with early treatment initiation, particularly through newborn screening programmes; patient-centred care, genetic counselling, and psychosocial support are integral to long-term disease management.

Key Highlights

• In Germany, Pompe Disease prevalent cases are projected to increase from 1,401 patients in 2025 to 1,510 patients in 2035, reflecting gradual improvement in diagnosis and patient survival.
• Increasing awareness, improved genetic testing, and expansion of rare disease screening programs are supporting earlier diagnosis across Germany.
• Current treatment landscape is primarily dominated by enzyme replacement therapies (ERTs), with growing focus on next-generation therapies offering improved efficacy and tissue penetration.
• Persistent unmet need exists for durable treatment options capable of addressing long-term muscle degeneration, respiratory decline, and variable response to existing ERTs.
• Emerging pipeline therapies, including gene therapies and enhanced GAA replacement approaches, are expected to reshape the future treatment paradigm.

Market Overview

• The Germany Pompe Disease market is projected to grow from USD 74 million in 2025 to USD 185 million by 2035, indicating substantial market expansion over the forecast period.
• Market growth is driven by:
• Increasing diagnosis and treatment rates among late-onset Pompe Disease patients
• Rising adoption of advanced and premium-priced enzyme replacement therapies
• Improved patient survival and long-term disease management
• Future market expansion will largely depend on innovations that improve long-term functional outcomes, reduce treatment burden, and address progressive muscle deterioration.

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Genzyme, a Sanofi Company
• Shionogi
• AskBio Inc.
• Amicus Therapeutics
• GeneCradle Inc.
• Astellas Gene Therapies